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Paraquat poisoning is a highly lethal toxicity despite advances in
critical care and efforts in extracorporeal elimination [1]. After
ingestion, paraquat is rapidly absorbed via the gastrointestinal tract
and reaches peak plasma concentrations within the 1st hour. In
many cases, by the time patients receive medical support; gastroin-
testinal decontamination is no longer possible.
Afterward, paraquat is actively absorbed by most vital organs,
and plasma concentration rapidly drops within about 4 hours
[2,3]. This duration must be considered the optimal period to use
extracorporeal elimination techniques. Fortunately, charcoal hemo-
perfusion, and to a lesser extent hemodialysis, can help eliminate
paraquat [2]. However, our experience indicates that most patients
do not receive extracorporeal elimination during this period.
Although charcoal hemoperfusion is the preferred method [2], it
is not readily available, even in many tertiary care centers. To use
this technique, a rapid patient transportation system is required.
In contrast, hemodialysis can be usedmore readily in some second-
ary care settings, so it is a good choice in the golden period. How-
ever, some problems can be encountered. Although central
venous access is easily attained, the unknown hepatitis viral
marker status of a patient is a common barrier to emergency hemo-
dialysis or charcoal hemoperfusion. It is necessary to prevent
contamination of hemodialysis equipment by infected patients
[4]. Because of the high mortality rate of paraquat toxicity and
the necessity of removing considerable amounts of it from the
bloodstream during the ﬁrst hours, we propose that hemodialysis
equipment be reserved for patients who are positive for hepatitis
B surface antigen and also be used for these patients. Although
there is a risk of nosocomial transmission of hepatitis B, this risk
is not very high [5]. In addition, hepatitis B immunoglobulin can
be used for protection immediately after the procedure if labora-
tory data indicate that the patient is not seropositive [6].Conﬂicts of interest: none.
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